Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cells-primed angiogenesis

Chondrosarcoma, a common malignant tumor, develops in bone. Effective adjuvant therapy remains inadequate for treatment, meaning poor prognosis. It is imperative to explore novel remedies. Angiogenesis is a rate-limiting step in progression that explains neovessel formation for blood supply in tumor microenvironment. Numerous studies indicate endothelial progenitor cells (EPCs) promoting angiogenesis and contributing to tumor growth. Basic fibroblast growth factor (bFGF), a secreted cytokine, regulates biological activity including angiogenesis and correlates with tumorigenesis. However, the role of bFGF in angiogenesis-related tumor progression by recruiting EPCs in human chondrosarcoma is rarely discussed. Here, we found bFGF induced vascular endothelial growth factor (VEGF) expression via FGFR1/c-Src/p38/NF-κB signaling pathway in chondrosarcoma cells, thereby triggering angiogenesis of endothelial progenitor cells. Our in vivo data revealed tumor-secreted bFGF promoting angiogenesis in both mouse plug and chick chorioallantoic membrane assay (CAM). Xenograft mouse model data, due to bFGF-regulated angiogenesis, showed bFGF regulating angiogenesis-linked tumor growth. Finally, bFGF was highly expressed in chondrosarcoma patients than normal cartilage, positively correlating with VEGF expression and tumor stage. Our study offers a novel therapeutic target for chondrosarcoma progression.
Source: Clinical Science - Category: Biomedical Science Authors: Source Type: research

Related Links:

Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
ConclusionWe have developed a reliable nomogram for determining the prognosis and treatment outcomes of chondrosarcoma patients that is superior to the traditional AJCC staging system.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 3 October 2019Source: Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyAuthor(s): Alireza Khooei, Shahriar Mohammadreza Sharifian, Mahdi Karimi Shahri, Shirin Taraz Taraz Jamshidi, Nooshin Sedaghat SharifiAbstractDedifferentiated chondrosarcoma is a rare primary bone neoplasm and it is extremely rare in paranasal sinuses and skull bones in particular. Herein we describe a case of dedifferentiated chondrosarcoma of the maxilla extending to the orbit in a 51 year-old man.
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - Category: ENT & OMF Source Type: research
We present the case of a large sternal defect after chondrosarcoma resection reconstructed with porcine acellular dermal matrix and soft tissue flaps, without rigid component, with excellent patient outcome through 2 years of follow-up.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Publication date: October 2019Source: Journal of Comparative Pathology, Volume 172Author(s): B.S. Cecco, L.C. Henker, C. De Lorenzo, C.I. Schwertz, R.M. Bianchi, F.V.A. da Costa, D. Driemeier, S.P. Pavarini, L. SonneSummaryFeline injection site sarcoma (FISS) is a mesenchymal neoplasm with highly malignant characteristics. These tumours originate in anatomical sites where there has been previous parenteral administration of medicinal substances or implantation of medical devices. The aim of this study was to investigate the epidemiological and pathological features associated with FISS in the southern region of Brazil. The...
Source: Journal of Comparative Pathology - Category: Pathology Source Type: research
Conclusions: For patients with EMC, surgery alone was associated with a higher risk of local recurrence. Therefore, we recommend optimal local therapeutic strategies upfront with both surgery and radiation therapy to reduce the risk of local and ultimately distant recurrence.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Soft Tissue Source Type: research
ConclusionsDespite a PFR at 12 weeks lower than expected, this randomized non comparative study shows a promising signal of benefit of REG in relapsed CS, with a median of PFS of 19 weeks and, an acceptable toxicity.Clinical trial identificationEudraCT: 2013-003910-42, NCT02389244.Legal entity responsible for the studyUNICANCER.FundingBayer HealthCare SAS.DisclosureF. Duffaud: Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Lilly; Travel / Accommodation / Expenses: Pharmamar; Travel / Accommodation / Expenses: Leo Pharma. J. Blay: Honoraria (self), H...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe trial met its primary endpoint. SU-NI is an active combination for the treatment of advanced selected STS patients, with 50% of patients free of progression at 6m. Further exploration of immunomodulatory strategies is warranted in selected sarcoma subtypes.Clinical trial identificationNCT03277924.Legal entity responsible for the studyGrupo Espa ñol de Investigación en Sarcomas (GEIS).FundingPfizer and BMS.DisclosureJ. Martin Broto: Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: PharmaMar; Honoraria (self), Speaker ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis study is continuing to enroll pts and will identify the recommended dose of ADCT-601. Updated results, including pharmacokinetic data, will be presented at the meeting.Clinical trial identificationNIH (https://clinicaltrials.gov/ct2/show/NCT03700294) October 9, 2018.Editorial acknowledgementEditorial support was provided by Sindhu Doppalapudi and Becky Salisbury at Fishawack Communications Ltd, funded by ADC Therapeutics Ltd.Legal entity responsible for the studyADC Therapeutics.FundingADC Therapeutics.DisclosureA.W. Tolcher: Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundIn many solid tumors, the setting of an immunosuppressive environment regulated by macrophages and immune checkpoints (ICP) is often a bad prognosis factor. Thus, targeting this immune environment led to the developments of new immunotherapies that raised high hopes for the treatment of solid tumors. Immunotherapy for chondrosarcoma (CHS) is comparatively less advanced partly because the immune environment of these rare tumors remains sparsely explored. However with their high resistance to conventional therapies CHS are typically tumors for which immunotherapies could be a solution. To get an exhaustive ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Biomedical Science | Cancer & Oncology | Chondrosarcoma | Science | Study